TY  - JOUR
PY  - 2016//
TI  - Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
JO  - New England journal of medicine
A1  - Lee, Joshua D.
A1  - Friedmann, Peter D.
A1  - Kinlock, Timothy W.
A1  - Nunes, Edward V.
A1  - Boney, Tamara Y.
A1  - Hoskinson, Randall A. Jr.
A1  - Wilson, Donna
A1  - McDonald, Ryan
A1  - Rotrosen, John
A1  - Gourevitch, Marc N.
A1  - Gordon, Michael
A1  - Fishman, Marc
A1  - Chen, Donna T.
A1  - Bonnie, Richard J.
A1  - Cornish, James W.
A1  - Murphy, Sean M.
A1  - O'Brien, Charles P.
SP  - 1232
EP  - 1242
VL  - 374
IS  - 13
N2  - Opioid-use disorder is a chronic relapsing condition that has serious public health consequences. Opioid dependence disproportionately affects U.S. criminal justice system populations, and relapse and overdose deaths occur at high rates after release from incarceration.1 Evidence-based opioid-agonist maintenance therapies for opioid dependence (methadone and buprenorphine) are effective in prison, jail, and community reentry (i.e., parole) settings2-5 but have historically been unavailable or discouraged among criminal justice clients.6-8 Extended-release naltrexone (Vivitrol, Alkermes), a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, was approved by the Food and Drug Administration in 2010 for the prevention of relapse to. . .<p />  <p>Language: en</p>
LA  - en
SN  - 0028-4793
UR  - http://dx.doi.org/10.1056/NEJMoa1505409
ID  - ref1
ER  -